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ABSTRACT
Exon arrays are regularly used to analyze differential
splicing events. GeneChip Gene 1.0 ST Arrays
(gene arrays) manufactured by Affymetrix, Inc. are
primarily used to determine expression levels of
transcripts, although their basic design is rather
similar to GeneChip Exon 1.0 ST Arrays (exon
arrays). Here, we show that the newly developed
Gene Array Analyzer (GAA), which evolved from
our previously published Exon Array Analyzer
(EAA), enables economic and user-friendly analysis
of alternative splicing events using gene arrays. To
demonstrate the applicability of GAA, we profiled
alternative splicing events during embryonic heart
development. In addition, we found that numerous
developmental splicing events are also activated
under pathological conditions. We reason that the
usage of GAA considerably expands the analysis
of gene expression based on gene arrays and
supplies an additional level of information without
further costs and with only little effort.
INTRODUCTION
Alternative splicing (AS) is a post-transcriptional process
based on the joining of exons of a gene in different com-
binations to generate various isoforms from a single
gene. It has been shown that most genes have at least
one alternative isoform (1), which can be expressed in a
tissue, development or sex-speciﬁc manner and fulﬁll dif-
ferent or even opposing functions (1–3). Traditional
microarrays are not capable of detecting alternative
spliced isoforms, since their probes target only small
regions at the 30-end of genes (30 arrays). In contrast,
whole-transcript arrays, such as exon arrays from
Affymetrix, Inc. (GeneChip Exon 1.0 ST Array),
contain probe sets (consisting of up to four probes) rep-
resenting every exon. Additional probe sets are provided
on exon arrays to allow identiﬁcations of internal splice
sites, retaining introns or putative exons. This approach
allows the detection of over 1.4 million expressed
sequences.
Recently, GeneChip Gene 1.0 ST Array (gene array)
was released by Affymetrix, Inc. This microarray
platform was designed to measure gene expressions
rather than expressions of single exons. However,
gene arrays are very similar to exon arrays in respect to
the hybridization protocol and coverage of annotated
genes (4,5). The majority of probe sets present on gene
arrays is identical to probes of high-quality annotation
(core annotation) of exon arrays, but probe sets for puta-
tive exons and genes are not integrated into gene arrays
(Figure 1A). Additionally, probe sets on gene arrays
consist of only two instead of four probes (Figure 1B).
Previous studies indicate that both exon and gene arrays
correlate well to 30 arrays in respect to gene expressions
[correlation of 0.80 as reported by (7)] and very highly to
each other at both gene and exon levels [R=0.94 and
R=0.91, respectively as reported by (8)]. This implies
that gene arrays are also capable of detecting differentially
expressed exons, but the coverage of individual exons is
limited compared with exon arrays (9). Although gene
arrays are more affordable than exon arrays or deep
sequencing, their intended usage focuses solely at the
gene expression level, which leaves additional information
contained in them untouched.
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Analyzer (EAA) (http://EAA.mpi-bn.mpg.de), an
easy-to-use web tool for analyzing exon arrays for differ-
ential expressed exons (10). Here, we describe the Gene
Array Analyzer (GAA), a versatile tool to analyze
GeneChip Array data at both gene and exon levels. To
demonstrate the applicability of GAA, we proﬁled
isoform switch events that occur during heart develop-
ment and cardiomyocyte differentiation of murine embry-
onic stem (ES) cells. We also used GAA to re-evaluate
already existing publicly available datasets, which
resulted in the detection of disease-related splicing events
to recapitulate the developmental splicing processes.
MATERIALS AND METHODS
Implementation of GAA
The analysis of gene arrays followed a similar approach as
our previous work with exon arrays (10). In brief, the
Affymetrix Power Tools (http://www.affymetrix.com)
were used for normalization, background correction and
summarization of raw CEL ﬁles uploaded to the GAA
server by the user. The ps- and the mps-ﬁles for gene
arrays were utilized. The ps-ﬁle contains a list of probe
sets for exon level, and the mps-ﬁle contains probe sets
grouped into transcript cluster, which represent a gene.
All probe set signals of a transcript cluster are used by
theAffymetrixPowerToolstoestimatethegeneexpression
signal. For the identiﬁcation of differentially expressed
exons, we applied the Splice Index (SI) (11). Gene level
normalized intensity (GNI) was calculated for each exon:
GNIij ¼
Eij
Gj
ð1Þ
where Eij is the exon signal for exon i in sample j. Gj is the
gene level signal in j. Using this value, the SI can be
calculated as follows:
SI ¼ log2
GNIiA
GNIiB
ð2Þ
where A and B are the two samples to compare. This
approach has been commonly applied in exon array ex-
periments on the ‘core’ annotation set (12–14). To avoid
inﬂated false positive results produced by the SI and other
algorithms (15), we used a set of ﬁlters as described by a
guideline of Affymetrix (16). Thus, genes that are not
Figure 1. (A) Probe sets on exon arrays are virtually grouped into three non-overlapping categories, namely ‘core’, ‘extended’ and ‘full’. The ‘core’
set covers well-annotated genes from RefSeq and full-length mRNAs, ‘extended’ cDNA alignments and ‘full’ gene predictions. The number of
covered genes on gene and exon array ‘core’ sets are very similar. However, exon arrays have a large number of additional probe sets for hypo-
thetical exons and genes (e.g. from GeneScan) in the ‘extended’ and ‘full’ sets. The numbers shown above were calculated using Galaxy’s (6) function
‘Proﬁle Annotations’ on the genomic positions of mouse gene and exon array probe sets. (B) Distribution of probes on 30, gene and exon arrays. The
red boxes represent exons of a hypothetical gene, spliced into three isoforms. 30 arrays have probes in the 30 region of a gene to measure gene
expressions. For gene and exon arrays, probes distributed across the entire length of the gene are summarized to measure gene expressions.
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expressed in any condition were ﬁltered out. This elimin-
ates incorrectly identiﬁed probe sets with high SI, which
are resulting from the background noise (i.e. low
signal-to-noise ratio). Cross-hybridizing probe sets and
probe sets with an abnormally high SI were discarded,
because they may not reﬂect true expression changes.
Furthermore, large differences in gene expression levels
can increase the noise resulting in false positives (11).
All ﬁlters are optional and can be modiﬁed by the user.
Since the initial introduction of EAA, we implemented
several additional features. Previously, analysis was
limited to pairwise comparisons, which we now extended
to up to four groups per analysis by implementing limma
(17) from the Bioconductor package, which has been ori-
ginally applied on exon arrays by Shah and Pallas (18).
Matching putative splicing events as found by GAA to
known splicing events is a critical step to distinguish
between false and true positives. For this purpose, we
added a table with known splicing events to the result
view. To implement this feature, we downloaded the
‘knownAlt’ track from the UCSC genome browser (19).
This track contains 132205 splicing events in human and
mouse, which are categorized into nine different event
types. In addition, we downloaded the transcript coordin-
ates from the AceView database (20) of human, mouse
and rat and identiﬁed 211098 splicing events by utilizing
ASTALAVISTA (21). Splicing events from both sources
were imported into MySQL tables. Additionally, we
added information about tissue-speciﬁc splicing events.
For this purpose, we analyzed the publicly available
tissue dataset from Affymetrix for human, mouse and
rat. Each dataset contains 11 tissues with three replicates
each. We compared each tissue against all other tissues as
a group using EAA. For all 11 3 datasets, we used the
Robust Multichip Average (RMA) (22) as a preprocessing
algorithm and the default settings of the EAA. A probe set
(exon) is considered as tissue-speciﬁcally (P<0.01)
expressed (SI>1) or skipped (SI< 1).
mESC culture and differentiation
The clone CM7/1 of J1 mouse embryonic stem cell
(mESC) line carrying the neomycin resistance gene
driven by cardiac alpha-myosin heavy chain promoter
was maintained and differentiated as previously described
(23). The selection of cardiomyocytes with 400mg/ml of
G418 (GIBCO) was initiated on 9 days after the initiation
of differentiation.
Animals
Hearts [E17.5, P1 and adult (2-month old)] were isolated
from individual C57BL/6 mice. All animal experiments in
this study were approved by the local animal care
committee.
Microarray experiment
Total RNA was prepared with TRIzol Reagent
(Invitrogen). The quality of extracted RNA was assessed
by the Agilent Bioanalyzer (Agilent Technologies). Three
hundred nanograms of total RNA from each sample was
processed for hybridization onto GeneChipMouse Gene
1.0 ST Array (Affymetrix) or GeneChipMouse Exon
1.0 ST Array according to the manufacturer’s protocol
and scanned. Raw and normalized data have been
submitted to GEO and are available under series
GSE33183.
AltAnalyze
For a comparison to the result of AltAnalyze, we down-
loaded the most recent release (2.0.4) from http://www
.altanalyze.org/. To reduce complexity, we excluded EB
from the analysis and compared ES to CB only. We
used the ENSEMBL release 55, since GAA is based on
this version. To retrieve all probe sets (not just signiﬁcant
ones), we set ‘Minimum alternative exon score’ and ‘Max
MiDAS/normalized intensity P-value’ to 1. All other par-
ameters were left as default settings.
Gene Ontology analysis
We used PantherDB (http://www.pantherdb.org/) to
identify up- and downregulated Gene Ontology terms.
All genes and exons, which were signiﬁcantly different
between any condition (F-statistic P<0.001), were used.
Hierarchical clustering
The normalized expression ﬁles were loaded onto MeV
(24) to ﬁlter for the 25% of genes with highest standard
deviations. The same software was used for hierarchical
clustering of samples by using Pearson’s correlation with
average linkage clustering. The dendogram was generated
by TreeGraph2 (25).
RESULTS
Gene Array Analyzer
The reliability of gene arrays compared to exon arrays has
been studied at the gene (7) and exon levels (9), suggesting
that gene arrays have the potential to proﬁle exon expres-
sion changes (8). Inspired by these studies, we reasoned
that gene arrays might be utilized to analyze alternative
splicing events with existing algorithms. We therefore
reconﬁgured our web server for exon array analysis (10)
to match requirements of gene arrays and named this new
tool GAA. To use GAA, the user only has to provide raw
CEL ﬁles. GAA is capable of performing a complete
analysis, including pre-processing (background correction,
normalization and summarization), ﬁltering, gene expres-
sion analysis, alternative splicing analysis and visualiza-
tion of spliced genes (Figure 2). Unlike the former
version of EAA, which was only able to perform a
pairwise comparisons, up to four groups per analysis
can be processed (Figure 3A). All groups can be
compared to each other individually by setting up a
contrast matrix. GAA allows graphical representation
of known isoforms within its built-in genome browser to
evaluate expressed isoforms, which is a critical step to dis-
tinguish between false and true positives. Moreover,
known splicing events from two different sources were
integrated into GAA to assess whether a differentially
2416 Nucleic Acids Research, 2012,Vol.40, No. 6expressed probe set may correspond to known splicing
events (Figure 3D). We also implemented exon array-
derived datasets from 11 different normal tissues contain-
ing differentially spliced exons to serve as a reference for
potential splicing events. The main features of GAA are
shown in Figure 3. A more detailed description can be
found in the ‘Materials and Methods’ section and in the
online help section of GAA (http://GAA.mpi-bn.mpg.de/
help.php).
Alternative splicing during heart development
Heart is the earliest organ in mammals to acquire func-
tionality in order to support survival. Although the heart
is a vital organ, very few studies have been published
up until recently to identify genome-wide alternative
splicing events (26,27). To gain further information
about alternative splicing during heart development,
we performed gene array experiments using hearts from
embryonic day 17.5 (E17.5), post-natal day 1 (P1), and
2-month-old male mice and compared these three devel-
opmental stages with each other at the gene and exon
levels. Analysis was conducted using GAA as described
in the ‘Materials and Methods’ section. We identiﬁed
2521 differentially expressed genes (DEGs) and 3452
probe sets [termed ‘differentially expressed exon (DEE)’
hereafter] as signiﬁcantly regulated (F-statistic
P<0.001). All signiﬁcant DEGs and DEEs are listed in
Supplementary Table S1, and the full result can be ac-
cessed at GAA online.
Next, we performed Gene Ontology analysis through
the PANTHER software (28). As reported by others
(27), signiﬁcantly enriched terms are not identical at the
gene and exon levels but do overlap with each other. We
found enrichments for system development, and helicase
activity at the exon level, whereas oxidoreductase activity
and receptor binding activity at the gene level. In agree-
ment with our data set, highly signiﬁcant terms in both
groups are metabolic process, developmental process,
cytoskeletal protein binding and structural constituent of
cytoskeleton, which are known to be important for the
development of heart (Supplementary Table S2).
Alternative splicing during cardiomyocyte differentiation
Heart is made up of cardiomyocytes, ﬁbroblasts, endothe-
lial and smooth muscle cells. To obtain a pure source
of cardiomyocytes, we differentiated J1 mouse
ES cells (strain 129S4/Jae; ATCC# SCRC-1010) to
cardiomyocytes and eliminated all non-cardiomyocyte
cells using a construct consisting of the cardiac alpha-
myosin heavy chain promoter driving the neomycin resist-
ance gene (23). Gene arrays were hybridized with
RNA obtained from undifferentiated ES cells (ES) (Day
0 before the induction of differentiation), embryonic
bodies (EB) (Day 7 after the induction of differentiation)
and cardiac bodies (CB) (14 days after the induction of
differentiation with spontaneous beating, which is a char-
acteristic of cardiomyocytes). Data were analyzed with
GAA as described in the ‘Materials and Methods’
section. The P-value of the F-test was used to identify
genes that are differentially expressed between any of the
three conditions. GAA identiﬁed 1 852 DEG and a rela-
tively low number of 166 DEE within the threshold
P<0.001 (Supplementary Table S1 and at GAA online).
The Gene Ontology analysis during differentiation of
cardiomyocytes shows that signiﬁcant terms at the exon
level represent a subset of the terms at the gene level.
The much higher number of DEG compared with
DEE might explain this observation. Terms found at
Figure 2. Work ﬂow of GAA. After uploading the raw CEL ﬁles to the GAA server, preprocessing is initiated. The Affymetrix Power Tools are
utilized for background correction, normalization and summarization at the gene and exon level. A P-value for each exon (probe set) is estimated to
determine whether an exon is expressed above background levels. In the next steps, ﬁlters are applied to eliminate false positives. GNI are passed to
limma for calculation of the SI and statistics. Results are imported into MySQL tables for visualization.
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and transcription factor activity, etc. One of the most sig-
niﬁcant biological process at the gene level was develop-
mental process. Other highly enriched terms were heart
development and muscle organ development, which are
expected terms during differentiation of cardiomyocytes
(Supplementary Table S2).
To demonstrate the usability of GAA, we selected a set
of genes with the highest difference at the exon level
between CB and ES as well as EB. The probe set with
Figure 3. In the ﬁrst two steps of an analysis, the user has to select the species and upload CEL ﬁles to the server (data not shown). (A) Afterwards,
names for the analysis and groups as well as a password to access the result are needed to be provided by the user. Each uploaded CEL ﬁle needs to
be assigned to its group by selecting a box. The groups are used to set up comparisons. After processing by GAA has ﬁnished, the user will receive a
link to access the result. (B) On the result page, thresholds for SI and P-value can be chosen to ﬁlter at the exon or gene levels. It is also possible to
search for certain genes, e.g by Gene Symbol. A table with all exons or genes meeting the thresholds will be shown on the same page (data not
shown). Each entry is linked to a page with more details, including links to other databases, SI of all exons of the gene and probe set sequences.
(C) This page also displays a box plot of GNIs of all exons of a gene, here shown on the example of Add3 which has been validated by reverse
transcription polymerase chain reaction (RT–PCR) (see text). Not shown here is the genome browser, which is also displayed on the same page (see
Figures 4B and 5B for examples). (D) A table shows the SI, P-value and known splicing events of all probe sets. (E) By clicking on a probe set ID in
the genome browser, exon sequences are shown. They can be used directly to design primers. Screen shots are modiﬁed to ﬁt the page. Additional
information on how to use GAA can be found in the online help section at http://gaa.mpi-bn.mpg.de/help.php.
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As shown in the GAA’s genome browser, several isoforms
of this gene are known (only two out of six isoforms are
shown in Figure 4B). The differentially expressed probe
set (probe set ID ‘10509631’) indicates that the longer
isoform of Capzb1 was expressed in CB while the corres-
ponding exon for this longer isoform was skipped in ES
and EB, thus, generating Capzb2 (29). The knownAlt
track and AceView also identiﬁed this splicing event as
indicated by the GAA-generated expression table. In
addition, the GAA detected tissue speciﬁcity of this
splicing event using the exon array dataset. The signiﬁ-
cantly higher expression values of this probe set were
recorded for heart and muscle compared with nine other
tissues. This ﬁnding is in agreement with the result in Ref.
(29), which reported that Capzb1 is predominately
expressed in muscle and cardiac tissue while the shorter
form is present in non-muscle tissues. Another study
found these two isoforms have distinct functions and
cannot replace each other (30).
Next, we reason that there should be a set of genes
whose expressions do not change but create different
isoforms with altered expression patterns during
cardiomyocyte differentiation, in which we termed this
phenomenon as ‘isoform switch’. To screen for such
genes, the following criteria were used: exons with
increasing or decreasing expression levels (SI>0.5,
P<0.05) of unregulated genes with opposite thresholds
(gene level fold-change < 0.5, P>0.05). As a result,
eight genes were selected (Figure 5A). To provide an
evidence for such isoform switched genes, we validated
the known cassette exon of Spna2 (Spectrin alpha 2)
by reverse transcription polymerase chain reaction (RT–
PCR) experiment (Figure 5B and C).
Comparison between heart development and
cardiomyocyte differentiation
The comparison of heart development and cardiomyocyte
differentiation using the same thresholds as described
Figure 4. Splicing during cardiomyocyte differentiation. (A) The probe set ‘10509631’ of Capzb shows one of the highest SI during cardiomyocyte
differentiation (CB compared to ES and EB). In contrast, the ﬂanking probe sets in all three cell lines show a similar GNI indicating that they are
expressed equally (in relation to the individual gene expression). (B) The integrated genome browser revealed that ‘10509631’ is targeting an exon,
which is skipped in the upper and included in the lower isoform. Literature search revealed that the longer isoform is known as cardiac and muscle
speciﬁc (see text). Both genome maps display a region of Capzb.
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(Figure 5D). The number of DEE derived from the
cardiomyocyte differentiation dataset was remarkably
smaller compared with the heart development dataset.
To further investigate the reasons for the high discrepancy
of DEE, we searched for genes that are involved in
‘RNA splicing’ (by Gene Ontology term GO:0008380).
Interestingly, we found only three genes that are regulated
during cardiomyocyte differentiation, but 34 splicing
factors were identiﬁed during development of the heart
(P=1 and P=0.04725, respectively, by right-tailed
Fisher’s exact test). Hierarchical clustering of these 37
genes shows the large difference among different samples
(Supplementary Figure S1).
Comparison to exon arrays
Previously, we described the identiﬁcation of eight
heart-speciﬁc splicing events using EAA and exon arrays
(10). For the current analysis, gene array data from the
same set of tissues were employed (http://www.affymetrix
.com) and used for a direct comparison between exon and
gene arrays. Independently validated splicing events were
compared to the result of the gene array analysis and are
listed in Supplementary Table S3. In the case of Idh3b,
gene array analysis indicated a wrong splicing event due
to insufﬁcient probe set coverage (Supplementary Figure
S2). However, in half of the observed cases, both types of
arrays identiﬁed identical splicing events.
The origin of samples which were used in the Affymetrix
tissue dataset has not been published. For a systematic
comparison between gene and arrays, we performed
exon arrays with the same samples as we used for
cardiomyocyte differentiation. First, we measured the cor-
relation at the gene and exon levels (Supplementary Figure
S3). As previously reported by others (8), we detected a
very high correlation at the gene level (of R=0.91)
and a slightly lower correlation at the exon level
(R=0.87). To identify DEG and DEE, we analyzed the
exon arrays with EAA using its default parameters. We
found 1,014 DEGs and 769 DEEs using the same cut-off
as for gene arrays (F-statistic P<0.001). The identiﬁed
genes and exons can be found in Supplementary Table
S4. Next, we asked how many DEGs and DEEs were
detected on both arrays. We identiﬁed 762 signiﬁcantly
Figure 5. (A) Plot represents GNI of eight selected probe sets, which are up and downregulated at the exon level during cardiomyocyte differen-
tiation but are expressed equally on the gene level (see text). (B) One such gene is Spectrin alpha 2 (Spna2), which is known to be spliced into many
isoforms. The parts of the 30-end of two isoforms is shown above. During cardiomyocyte differentiation, probe set ‘10470885’ is differentially
expressed while the expression level of the gene does not change. (C) The RT-PCR validation of the cassette Exon 51 (according to
ENSMUST00000113719) in ES cells compared with CB (upper). Additional primers were used to measure the global gene expression of Spna2
(lower). (D) Venn diagrams show the number of DEG, DEE and spliced genes during heart development and differentiation of cardiomyocytes.
A gene or exon was considered as regulated if any of the three conditions in the two datasets differs signiﬁcantly (F-statistic P<0.001).
2420 Nucleic Acids Research, 2012,Vol.40, No. 6regulated genes by both GAA and EAA, which corres-
ponds to 76% of all DEG on exon arrays. For a compari-
son at the exon level, we mapped the signiﬁcantly
regulated gene array probe sets to ENSEMBL exons. Of
these 89 unique ENSEMBL exons, 14 were identiﬁed as
DEE by exon array probe sets as well (Supplementary
Table S5 for a comparison). We performed RT–PCR ex-
periments for nine splicing events and were able to
validate all events. To demonstrate that gene arrays are
capable of detecting splicing events that were not found
with exon arrays, we randomly chose 14 probe sets that
show no signiﬁcant regulation on exon arrays. Of these,
two splicing events were validated as true positive results.
Results of RT–PCR experiments can be found in
Supplementary Figure S4 and the used primer pairs in
Supplementary Table S6.
Comparison to other software products
Since the idea of using gene arrays for the analysis of al-
ternative splicing events is new, there are only a very
limited number of other products that can be directly
compared to GAA. FIRMAGene, a modiﬁcation of
FIRMA to gene arrays, represents an alternative
approach, although it is an algorithm not a software
product (9). Since there is no ‘gold standard’ dataset, a
direct comparison between FIRMAGene and the use of
Splice Indices employed by GAA is not possible.
While we were building GAA, a software work ﬂow
became available that can be used to analyze gene arrays
as well as exon arrays at the gene and exon levels (31). The
work ﬂow consists of two products: ‘AltAnalyze’ for
pre-processing and statistic analysis of gene arrays; and
DomainGraph for visualization of downstream analysis
(e.g. miRNA predicted binding sites, pathway analysis
and protein domain information). Compared to this
work ﬂow, which requires a manual installation to the
work station of the users, GAA users do not need to
worry about the computational power of analysis
because all calculations are carried out through server
machines, which should minimize the requirement for
high-end, powerful computers at the user side.
Furthermore, since GAA is completely browser based,
no set up on the user side is required, which avoids
time-consuming operations, such as downloading annota-
tion ﬁles and other relevant and required ﬁles for process-
ing of gene array data. Another point is that AltAnalyze is
a stand-alone application that provides the conﬁdentiality
of experimental data. To cope with conﬁdentiality
concerns, the uploaded CEL ﬁles are password protected
and are kept at the server for 1 week, which can be
extended through request by users, and will be eliminated
thereafter. Moreover, users can use pseudo-sample names
to further increase the conﬁdentiality. Unlike AltAnalyze
and DomainGraph, GAA provides mRNA sequences of
exons upstream and downstream of the identiﬁed differ-
entially expressed exon in a new window (Figure 3E). This
feature allows a user to simply copy and paste sequences
to a primer designing program, such as ‘Primer3’ (32), to
obtain a set of primers for the validation by RT–PCR
experiments.
To compare the result of AltAnalyze with GAA, we
analyzed our gene arrays as described in the ‘Materials
and Methods’ section. Since AltAnalyze uses SI>1 and
P<0.05 as default thresholds, we also applied these values
for the GAA result. Under these thresholds, we found
1707 regulated probe sets using GAA and 830 using
AltAnalyze. Of which, 312 were found with both tools.
To evaluate the true positive rate of both tools, we
checked which probe sets match to known splicing
events. In all, 17% of the probe sets detected as differen-
tially expressed with both tools and 15% of the probe sets
detected with either tool match to known splicing events.
We also compared the result to our seven validated
RT–PCR experimental results, which show differences
between ES and CB. Two of these DEEs were also
identiﬁed by AltAnalyze, further three show regulation
but no signiﬁcant P-value. The other three DEEs appear
not in the result of AltAnalyze. A direct comparison of the
results can be found in Supplementary Table S7.
Aberrant alternative splicing events under pathological
conditions
The major advantage of GAA is that it only requires
Affymetrix CEL ﬁles. In other words, it is possible to
re-evaluate previously published gene array data, which
were analyzed at the gene level but not at the exon level.
Hence, the information about changes in alternative
splicing events can be obtained without additional experi-
ments. As a proof-of-principle for such an approach, we
re-analyzed public datasets dealing with various patho-
logical conditions of the heart using GAA and
compared the results to the dataset of heart development
(Figure 6A).
Phosphoinositide 3-kinase (PI3K) is essential for the
heart development and plays an important role for the
induction of physiological cardiac hypertrophy (33).
Pretorius et al. (34) studied whether loss of PI3K makes
the heart susceptible to atrial ﬁbrillation (AF) in a mouse
model of dilated cardiomyopathy (DCM). To evaluate
molecular changes, the authors analyzed transcriptomes
of the left and right atria by gene arrays. Essentially, the
authors found that a reduction of PI3K is correlated with
a reduction of heart weight, although the heart functions
normally. However, combination of PI3K loss and DCM
leads to a more severe phenotype than DCM alone. We
obtained the raw CEL ﬁles from the Gene Expression
Omnibus (GSE12420) and analyzed them with GAA
using the default settings. We found 565 DEEs and 2285
DEGs between Mst1 (mammalian sterile 20-like kinase 1
overexpression as a model for DCM) and PI3K knock-out
and Mst1-PI3K (Mst1 overexpression and PI3K
knock-out) compared to the NTg (non-transgenic) mice
(Supplementary Table S8).
Next, we used our previously published gene array data
(GSE30428) of right ventricular hypertrophy induced by
using pulmonary artery clipping (PAC) (35). In this data
set, we found 105 DEGs and 419 DEEs using the same
thresholds as above (P-value of the F-test<0.001)
(Supplementary Table S8).
Nucleic Acids Research,2012, Vol.40, No. 6 2421The comparison of the results of the above two studies
with our study of heart development identiﬁed 268
overlapping genes among the three groups, but only 29
probes showing similar expression patterns at the exon
level (Figure 6B).
DISCUSSION
In our study, we describe a simple and efﬁcient way to
analyze splicing events using the widely applied gene
arrays. Gene arrays were originally designed to measure
genome-wide expression changes. However, their probe
design also allows for the analysis of changes at the
exon level to identify alternative splicing events. Gene
arrays have limitations due to the lower number of
probes per probe set, less probe sets per gene and no
probes for putative genes in comparison to exon arrays,
but they are much cheaper to use. Furthermore, numerous
datasets from gene arrays are available, which have not
yet been exploited to study differential splicing events.
The applicability of GAA was demonstrated by
analyzing datasets from heart development and cardio-
myocyte differentiation. We were able to identify DEGs
and DEEs in both datasets and illustrated how the graph-
ical output of GAA helps to recognize different isoforms.
Gene arrays are not limited to a priori known splicing
events, which may lead to the detection of de novo
isoforms. To support such novel discoveries, GAA
provides the built-in genome browser and the inclusion
of known splicing events to easily separate known and
novel splicing isoforms.
Our own data (Supplementary Figure S3) and others’
(7–9) demonstrated that gene arrays provide a comparable
signal for exon expression as exon arrays. To demonstrate
this potential, we analyzed similar data sets by using both
types of arrays and compared the outcome on eight
validated examples (Supplementary Table S3). As
expected, gene arrays were able to identify most
splicing events, although one splicing event was falsely
recognized because of the lower probe set coverage. To
further evaluate the performance of gene arrays
compared to exon arrays, we analyzed the same data set
of cardiomyocyte differentiation with exon arrays.
We compared the number of DEGs and DEEs identiﬁed
by both array types. At the gene level, we found less DEG
with exon arrays compared to gene arrays. The reasons for
this difference have been discussed elsewhere (7). At the
exon level, we found 14 DEEs with both arrays and
validated nine splicing events by RT–PCR experiments
(Supplementary Figure S4). In addition, we performed
RT–PCR experiments for further 14 DEEs. Of which,
Figure 6. Gene and exon expression changes under pathological conditions. (A) Hierarchical clustering of gene arrays of different studies. The data
set from cell culture experiments are clearly separated from those derived from whole hearts. In addition, hearts at early developmental stages are
distant from pathological conditions and adult hearts. (B) Venn diagrams of regulated genes under three different studies. Only genes that are
signiﬁcantly regulated (P<0.001 in both comparisons) and show the same trend of differentially expression (fold change < 0.5 or >0.5 in the
compared conditions) are counted.
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splicing events that could not be detected by exon arrays
could be identiﬁed and validated by gene arrays.
AltAnalyze is a stand-alone software package to
analyze different types of microarrays, including gene
arrays, for alternative splicing. We compared the result
of GAA with AltAnalyze side-by-side (Supplementary
Table S6). Regarding known splicing events, both tools
discovered the same proportion. However GAA found
48% more DEEs than AltAnalyze using the same thresh-
olds. Five out of seven validated splicing events between
ES and CB were not signiﬁcant or not found with
AltAnalyze. The difference between both tools originates
from different annotations and ﬁlters. Furthermore,
AltAnalyze uses ‘constitutive exons’ instead of all core
exons to estimate the gene expression, which inﬂuences
the calculation of the SI. Since we cannot test all
putative spliced exons, it is not possible for us to
compare comprehensively with other tools. However, we
showed by RT–PCR validations that GAA identiﬁes
splicing events reliably and we believe that GAA outper-
forms AltAnalyze in respect to usability.
In the comparison between heart development and
cardiomyocyte differentiation, we made an interesting ob-
servation: although 275 genes showed statistically signiﬁ-
cant differences among both related conditions
(Figure 5D), only very limited number of exons (six
exons) matched both processes. One might speculate
that alternative splicing is a very common process by
which genes respond to different conditions. This hypoth-
esis is also quoted frequently to explain discrepancies
between transcriptomics and proteomics datasets (36).
To further investigate the discrepancy, we searched for
regulated splicing factors and found a signiﬁcant enrich-
ment during heart development, but not during cardio-
myocyte differentiation (Supplementary Figure S1). One
of the strongly regulated splicing factors in the adult heart
is A2bp1 (7.36 fold upregulated), which encodes the Fox-1
protein. Fox-1 is known to be expressed in the adult
mouse heart (37) and involved in the post-natally devel-
opment of the heart (27). Other regulated splicing factors
are the serine/arginine-rich family (Snrnp27, Sfrs2, Srsf5
and other) and the heterogeneous nuclear ribonucle-
oproteins (Hnrnpa1, Hnrnpk and other) of which both
can act as splicing activator and silencer by binding to
short cis-motifs on the pre-mRNA [reviewed in (38)].
These regulated splicing factors in adult hearts may have
caused signiﬁcantly more splicing events, which cannot be
observed during cardiomyocyte differentiation.
In addition, we found genes that did not show differ-
ences of expression levels during differentiation of cardio-
myocytes but underwent alternative splicing, in which we
named this phenomenon to be ‘isoform switch’. The gene
‘Spna2’ is an example of such phenomenon. In our study,
we identiﬁed an isoform switch (inclusion of Exon 51
upon the differentiation of ES cells into beating cardio-
myocytes), which was validated by an RT–PCR experi-
ment (Figure 5C). The spliced exon lies in the spectrin/
alpha-actinin domain (IPR018159; 47-2,315aa) at position
2217–2237aa, on the last of 20 repeats. A previous study
demonstrated that homozygous mice appear healthy and
morphologically normal when Exon 25 27 of Spna2,
which lays downstream of the spectrin/alpha-actinin
domain (1154–1189aa, which corresponds to repeat 10)
and named CCC (calpain, caspase, calmodulin) domain,
are deleted in the mouse (39). However, in rat hearts, an
insertion of 20 aa exists next to repeat 10 called ‘alpha
II-SH3i’, which is important for intracellular targeting of
Connexin 43 to gap junctions and suspected to be a po-
tential target for stress signaling pathways (40). Inclusion
or exclusion of exon 51 might affect localization of Spna2
encoded ‘alpha II-spectrin’ at the Z disc and the plasma
membrane of myoﬁbrils (41), and thereby biological
properties of cardiomyocytes. It will be of interest to
study functional consequences of differences in the distri-
bution of isoforms during tissue development. Application
of GAA might serve as a starting point for such
approaches using existing data sets.
We obtained CEL ﬁles from studies of pathological
conditions of dilated cardiomyopathy (34) and right ven-
tricular hypertrophy (35), which have been analyzed at the
gene but not at the exon level. Since these experiments
used different parts of the heart and have been conducted
at different laboratories with animals of different genetic
backgrounds, a direct comparison between all experiments
needs careful evaluation (Figure 6A shows the similarity
between all samples). Yet, comparison of datasets at the
gene level revealed that some genes showed the same ex-
pression pattern during the heart development and under
pathological conditions. However, this correlation was
somewhat lost when the comparison was made at the
exon level (Figure 6B). In contrary to the popular belief
that there is a re-initiation of embryonic gene expressions
under pathological conditions (42,43), such trend does
hold at the gene level but not so well at the exon level.
This indicates that developmental alternative splicing
events are not activated to full extent under pathological
conditions. Hence, the activation of the fetal gene
program under stress conditions is incomplete in respect
to speciﬁc isoforms and represents a distinct state that can
be distinguished from the regular developmental program.
These ﬁndings further underline that changes in the tran-
scriptome originate from gene expressions, but a care must
be taken at the exon level by taking into account for al-
ternative splicing events.
Up until recently, high-throughput transcriptome
studies mostly concentrated on changes in gene expres-
sion. This trend has changed dramatically with the intro-
duction of RNA-seq using deep sequencing technology,
which uncovered that over 93% of genes have isoforms
(1) indicating that alternative splicing events are more
common than one anticipated. Although RNA-seq tech-
nology is improving constantly, results cannot be analyzed
without proper bioinformatical analysis, which imposes a
hurdle for experimental biologists. GAA is an easy to use
tool that allows experimental biologists with limited bioin-
formatical skills to detect new splicing isoforms. GAA is a
one-stop-shop for analysis of gene arrays to which a user
can upload CEL ﬁles of gene arrays. Through a click of
the mouse, a list of analytical methods can be selected.
DEEs are indicated by box-and-whisker plot (Figure 3C)
and by the genome viewer (Figure 5B) to identify locations
Nucleic Acids Research,2012, Vol.40, No. 6 2423of individual exons in the genome. We reason that GAA is
a valuable tool for biologists and adds another layer of
analysis to gene array without additional costs. The web
interface of GAA is easy to use, requires no set up and is
freely available at http://GAA.mpi-bn.mpg.de.
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